A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
14 Jul 2021
14 Jul 2021
Historique:
pubmed:
21
7
2021
medline:
21
7
2021
entrez:
20
7
2021
Statut:
epublish
Résumé
Vaccines against SARS-CoV-2 have been distributed at massive scale in developed countries, and have been effective at preventing COVID-19. Access to vaccines is limited, however, in low- and middle-income countries (LMICs) due to insufficient supply, high costs, and cold storage requirements. New vaccines that can be produced in existing manufacturing facilities in LMICs, can be manufactured at low cost, and use widely available, proven, safe adjuvants like alum, would improve global immunity against SARS-CoV-2. One such protein subunit vaccine is produced by the Serum Institute of India Pvt. Ltd. and is currently in clinical testing. Two protein components, the SARS-CoV-2 receptor binding domain (RBD) and hepatitis B surface antigen virus-like particles (VLPs), are each produced in yeast, which would enable a low-cost, high-volume manufacturing process. Here, we describe the design and preclinical testing of the RBD-VLP vaccine in cynomolgus macaques. We observed titers of neutralizing antibodies (>10
Identifiants
pubmed: 34282417
doi: 10.1101/2021.07.13.452251
pmc: PMC8288147
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007387
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-006131
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014051
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-027406
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-002740
Pays : United States
Déclaration de conflit d'intérêts
Competing interests J.C.L. has interests in Sunflower Therapeutics PBC, Pfizer, Honeycomb Biotechnologies, OneCyte Biotechnologies, QuantumCyte, Amgen, and Repligen. J.C.L’s interests are reviewed and managed under MIT’s policies for potential conflicts of interest. J.M.S. is an employee of the Bill & Melinda Gates Medical Research Institute. H.K. is an employee of the Bill & Melinda Gates Foundation. Sumi Biswas is the CEO and co-founder of SpyBiotech Ltd. which holds the exclusive rights for the use of Spytag/Spyctacher in the field of vaccines. Lesley Bowman is an employee of SpyBiotech Ltd.
Références
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
ACS Cent Sci. 2021 May 26;7(5):757-767
pubmed: 34075345
ACS Nano. 2021 Feb 23;15(2):2738-2752
pubmed: 33464829
Nat Commun. 2021 Jan 22;12(1):542
pubmed: 33483491
Nat Biotechnol. 2019 May;37(5):498-501
pubmed: 31053815
Nature. 2021 Apr;592(7856):667-668
pubmed: 33883710
Cell Rep. 2021 Feb 2;34(5):108699
pubmed: 33485405
PLoS Negl Trop Dis. 2020 Jul 29;14(7):e0008548
pubmed: 32726304
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34493582
Nat Commun. 2021 Mar 3;12(1):1403
pubmed: 33658497
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
Biotechnol Bioeng. 2022 Feb;119(2):657-662
pubmed: 34780057
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
Nat Med. 2021 Jun;27(6):1055-1061
pubmed: 33875890
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Vaccine. 2020 Nov 25;38(50):7892-7896
pubmed: 33139139
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
Nature. 2020 Oct;586(7830):572-577
pubmed: 32726802
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
J Immunol. 1998 Jan 15;160(2):870-6
pubmed: 9551923
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8
pubmed: 9861007
J Immunol Methods. 2007 Jun 30;323(2):139-46
pubmed: 17512533
Cell. 2020 Aug 6;182(3):722-733.e11
pubmed: 32645327
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
Vaccine. 2017 Jun 27;35(30):3726-3732
pubmed: 28578824
Chem Biol. 2008 Mar;15(3):201-2
pubmed: 18355715
Lancet. 2021 Feb 20;397(10275):682-694
pubmed: 33524311
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Front Immunol. 2019 Dec 12;10:2931
pubmed: 31921185
Nat Commun. 2021 Feb 24;12(1):1260
pubmed: 33627662
Curr Opin Biotechnol. 2018 Oct;53:50-58
pubmed: 29277062
J Virol. 2021 Mar 16;95(11):
pubmed: 33727331
PLoS Med. 2021 Oct 1;18(10):e1003769
pubmed: 34597298
Lancet. 2021 Feb 13;397(10274):562-564
pubmed: 33516284
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
JAMA. 2021 Apr 6;325(13):1318-1320
pubmed: 33635317
Ann Pharmacother. 2018 Jul;52(7):673-680
pubmed: 29457489
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
Vaccine. 2006 Apr 24;24(17):3457-60
pubmed: 16530299
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Methods Mol Biol. 2017;1494:15-27
pubmed: 27718183